Amgen Inc (AMGN) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla f...
Amgen Inc's revenue increased 10.0% year over year, from $33.42B to $36.75B.
Net income increased 88.5% over the same period, from $4.09B to $7.71B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 60% in total.
Total debt decreased by 11.6% to $50.01B.
The debt-to-equity ratio stands at 5.78, indicating a high leverage profile.
Operating cash flow declined 13.3% to $9.96B.
Amgen Inc maintains a strong net profit margin of 21.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $8.50B+1.4% | $2.83B | $3.84B | $626.0M | $3.57B | $90.88B | $56.85B | $7.53B |
| Q4 FY2024 | $9.09B+6.9% | $627.0M | $5.97B | $2.31B | $4.77B | $91.84B | $56.55B | $5.88B |
| Q1 FY2025 | $8.15B-10.3% | $1.73B | $5.18B | $1.18B | $1.39B | $89.37B | $54.01B | $6.21B |
| Q2 FY2025 | $9.18B+12.6% | $1.43B | $6.17B | $2.66B | $2.28B | $87.90B | $53.76B | $7.43B |
| Q3 FY2025 | $9.56B+4.1% | $3.22B | $6.47B | $2.53B | $4.68B | $90.14B | $52.43B | $9.62B |
| Q4 FY2025 | $9.87B+3.2% | $1.33B | $6.89B | $2.72B | $1.60B | $90.59B | $50.01B | $8.66B |
| Q1 FY2026 | $8.62B-12.6% | $1.82B | $5.87B | $2.67B | $2.19B | $92.50B | $57.32B | $9.19B |
| Q2 FY2026 | $10.05B+16.7% | $2.38B | $7.24B | $3.51B | $4.00B | $95.64B | $57.30B | $11.69B |
Balance Sheet Summary (Q2 FY2026)
Amgen Inc (AMGN) Financial Statements & Revenue History
Amgen Inc (AMGN) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry trading at $430.01 with a market capitalization of $232. This page provides 42 historical financial statements for Amgen Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Amgen Inc reported revenue of $36.8 billion, representing 10.0% year-over-year growth. The net profit margin of 21.0% reflects strong profitability. The debt-to-equity ratio of 5.78 signals high leverage.
AMGN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Amgen Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether AMGN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track AMGN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Amgen Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of AMGN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use AMGN Financial Data
Investors use Amgen Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare AMGN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how AMGN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View AMGN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Amgen Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.AMGN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.